Health and Healthcare

Cramer's #3 Speculative Stock for 2007

Tonight Cramer continued his quest of delivering his favorite TOP 3 SPECULATIVE STOCKS FOR 2007.  Cramer started off with his #3 pick, or the second runner up for the speculative stocks.

Savient Pharma (SVNT) is his #1 pick.  He said it is up $4.00 and has been on a tear.  It is up against competition, and you can’t put more than 20% of your mad Money in any speculative stock and he thinks you need a basket of speculative stocks.  With 20% geared toward speculative stocks, you should still have 4 others.  Out of these you can expect one to scream and one to go bust.  Cramer says management is good because they sold off a drug for more than it was worth then cut the number of shares with a Dutch tender.  Their phase III gout drug looks promising and Cramer said there hasn’t been a gout treatment in about 40 years and there are 3 to 5 million Americans with gout.  Phase II results were amazing, and if they have 35% market penetration he thinks it will be $200 million to $400 million and the stock could double.

Below are his picks from Wednesday and Thursday for Growth and Value Picks for 2007:
#1 growth pick is the New York Stock Exchange (NYSE).
#2 is Apple (AAPL).
#3  is Cisco Systems (CSCO).

If you want to read through to the top VALUE PICKS for 2007 that Cramer gave on Wednesday night, here is the list:

1) Altria (MO)
2) Goldman Sachs (GS)
3) Halliburton (HAL)

Jon C. Ogg
January  5, 2007

Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)

Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.

Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.

Click here now to get started.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.